Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05707442

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)

The aim of this study is to assess the efficacy of stent implantation versus medical therapy on idiopathic intracranial hypertension with venous sinus stenosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing Tiantan Hospital

Beijing, Beijing Municipality, 100010, China

Location status: Recruiting

Location contact

Dapeng Mo, MD

CONTACT

[email protected]

+8613691419036‬

About this study

The SIMPLE is a multicentered, prospective, randomized, open-label, blinded end-point clinical trial. A total of 74 patients with idiopathic intracranial hypertension (IIH) and venous sinus stenosis (VSS) for more than 2 months will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups (stenting or medical therapy) after offering informed content.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject Eligibility Criteria
  • Diagnosis of IIH by modified Dandy criteria about for more than 2 months
  • Lumbar puncture opening pressure ≥250 mmH₂O within 6 weeks before enrollment
  • Normal cerebrospinal fluid (CSF) composition
  • Neuroimaging showing normal brain parenchyma without hydrocephalus, mass, or any structural lesion and no evidence of meningeal enhancement on CT or MRI
  • Localized venous sinus stenosis (VSS) with stenotic degree ≥ 50% on DSA, and pressure gradient across stenosis ≥ 8 mmHg
  • Patients or their relatives signed written informed consent
  • Ophthalmic Eligibility Criteria:
  • At least one eye had the presence of papilledema
  • At least one eye of visual field loss: PMD ranging from - 2dB and below; decreased visual function on automated perimetry was reproducible with a false-positive rate of no more than 15%
  • Visual acuity above 20 / 200 (≥ 39 letters)

Exclusion criteria

  • Subject Exclusion Criteria
  • Previous surgery for IIH, including optic nerve sheath fenestration (ONSF), CSF shunting, decompressive craniectomy or venous sinus stenting
  • Progressive or rapid visual loss needed urgent surgical intervention; if delay>24-48 h consider interim lumbar drain (for rapid visual loss only).Surgical options to consider: CSF diversion or optic nerve sheath fenestration
  • Visual loss due to other etiologies (eg, retinal drusen, retinal and optic neuropathy, cataracts, etc)
  • Other condition requiring the use of diuretics, steroids or other drugs to reduce intracranial pressure
  • DSA showed diffused venous sinus stenosis, cortical or deep vein stenosis
  • A history of severe thyroid disease and iodine allergy
  • Pregnant or lactating women
  • Severe cardiopulmonary, liver or kidney failure
  • Known hereditary or acquired haemorrhagic diathesis
  • Known hereditary or acquired thrombophilia
  • Platelet counts or coagulation abnormality
  • Major surgery or severe trauma or any traumatic brain injury within the previous 14 days
  • A history of cerebral hemorrhage, arteriovenous malformation, intracranial aneurysm or tumor
  • Other life threatening illness (eg, advanced cancer) likely to lead to death within a few months; the physical, psychological and social status of patients may affect follow-up (eg, drug addiction, advanced malignant disease, no telephone, no family, etc); cannot tolerate general anesthesia
  • Increased intracranial pressure due to other secondary factors
  • Ophthalmic Exclusion Criteria:
  • Current intraocular pressure > 28mmHg or previous intraocular pressure > 30mmHg
  • Refractive error spherical power greater than -6.0D or +6.0D and astigmatism greater than 3.0D, except for the following cases:
  • Myopia of - 6.0D to - 8.0D with the following: 1)There was no myopia related disease that can lead to decreased vision under the eyeground microscope (eg, scleral staphyloma, retinal thinning at the posterior pole, and moderate to severe disc tilt); 2) The patient wore contact lenses of appropriate degree for all visual field examinations.
  • Hyperopia of +6.0D to +8.0D with the following: 1) The presence of a well characterized peri optic disc edematous halo, as opposed to crowded small optic discs or other features of decreased visual acuity associated with hyperopic changes, was at the discretion of the site investigator or reading center leader (or his designee); 2) The patient wore contact lenses of appropriate degree for all visual field examinations.
  • Examination visible or past medical history known to have large optic disc drusen (persistent optic disc edema can present with small optic disc drusen, as low numbers are acceptable for inclusion and to be determined by the investigator to be unrelated to vision loss)

Treatment and study plan

Stent Implantation

Procedure

Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).

Acetazolamide-based medical therapy

Drug

The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.

Weight Loss

Behavioral

The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.

Primary outcomes

  1. Perimetric Mean Deviation (PMD)

    Time frame: 6 months

    The change in perimetric mean deviation (PMD) from baseline to 6 month in the eye with the most severe visual loss at baseline.

Secondary outcomes

  1. Cerebrospinal Fluid (CSF) Opening Pressure

    Time frame: 6 months

    The change in intracranial pressure measured by lumbar puncture opening pressure from baseline to 6 months.

  2. Papilledema Grade: Frisén grade(0-5 scores,and higher scores mean worse outcome)

    Time frame: 6 months

    The change in papilledema measured by Frisén grade from baseline to 6 months

  3. Retinal Nerve Fiber Layer Thickness

    Time frame: 6 months

    The change in thickness of retinal nerve fiber layer measured by optical coherence tomography (OCT) from baseline to 6 months.

  4. Total Retinal Thickness

    Time frame: 6 months

    The change in thickness of total retina measured by optical coherence tomography (OCT) from baseline to 6 months.

  5. Visual Acuity: National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25, minimum and maximum values: 0-100 points, higher scores mean a better visual function)

    Time frame: 6 months

    The change in vision measured by National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) from baseline to 6 months.

  6. Visual Acuity: 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) (minimum and maximum values: 0-100 points, higher scores mean a better visual function)

    Time frame: 6 months

    The change in vision measured by 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)from baseline to 6 months.

  7. Headache: Headache Impact Test-6 (HIT-6, minimum and maximum values: 36-78 points, higher scores mean greater headache severity)

    Time frame: 6 months

    The change in headache measured by Headache Impact Test-6 (HIT-6) questionnaire from baseline to 6 months.

  8. Pulsatile tinnitus: Tinnitus Handicap Inventory (THI, minimum and maximum values: 0-100 points, higher scores mean more serious tinnitus disability)

    Time frame: 6 months

    The change in pulsatile tinnitus from baseline to 6 months;pulsatile tinnitus was assessed using the Tinnitus Handicap Inventory (THI), which is a self-report measure that can be used in a busy clinical practice to quantify the impact of tinnitus on daily living.

Other outcomes

  1. Functional health status and quality of life:EuroQol five dimensions questionnaire (EQ-5D,0-100,higher scores mean a better outcome)

    Time frame: 6 months

    The change in functional health status and quality of life measured by EuroQol five dimensions questionnaire (EQ-5D) from baseline to 6 months

  2. Cost-effectiveness analysis (mean costs per patient)

    Time frame: 6 months

    The indicator of cost-effectiveness analysis refers to the mean costs per patient.

  3. Cost-effectiveness analysis (quality-adjusted life years)

    Time frame: 6 months

    The indicator of cost-effectiveness analysis refers to the quality-adjusted life years.

  4. Cost-effectiveness analysis (the cost saving per extra patient with a good outcome)

    Time frame: 6 months

    The indicator of cost-effectiveness analysis refers to the cost saving per extra patient with a good outcome.

  5. Cost-effectiveness analysis (the cost saving per additional quality-adjusted life year)

    Time frame: 6 months

    The indicator of cost-effectiveness analysis refers to the cost saving per additional quality-adjusted life year.

Study contacts

Contact information is provided by the study sponsor or research team.

Xu Tong, MD

CONTACT

[email protected]

+8617611338800

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Feb 1, 2023
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.